Chatfeild-Roberts: How Apple could make or break your portfolio

clock

Investors are concerned recent sharp moves in Apple's share price are distorting returns for the wider US market, suggesting some indices may have to be rebalanced to lessen the tech giant's dominance.

Apple saw its share price hit a record $644 on 10 April, and although shares have subsequently dropped back some 11%, the stock remains up 42% year-to-date ahead of today's Q2 earnings figures. This price volatility has increased concerns the world's largest company by market capitalisation, at $550bn, carries excessive risks for the performance of the entire S&P 500 index. Some US analysts have warned even a small squeeze on margins could have a significant knock-on impact on wider US equity performance. Jupiter's chief investment officer John Chatfeild-Roberts said although the U...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot